{"entity":{"id":"nct06722911","kind":"trial","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Zhejiang Provincial People's Hospital, now recruiting.","summary":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer is a phase 2, interventional study registered as NCT06722911 by Zhejiang Provincial People's Hospital, with a registry enrolment figure of 57 participants, started 2024-11-15 and due to reach its primary completion in 2028-09-30. Interventions recorded: Nimotuzumab; AG. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: disease-free survival (DFS). Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06722911","url":"https://clinicaltrials.gov/study/NCT06722911"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06722911","phase":"2","setting":"Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study","sponsor":"Zhejiang Provincial People's Hospital","enrolled":57,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06722911/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}